Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  FUJIFILM Holdings Corporation    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly in deal to supply COVID-19 drugs to low-income countries

10/08/2020 | 10:32pm EST
FILE PHOTO: Eli Lilly logo is shown on one of their offices in San Diego

(Reuters) - Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.

As part of the deal, Lilly said it will make antibody therapies available to lower-income countries prior to April 2021, but did not elaborate on the number of doses. Separately, Fujifilm Holdings Corp said its facility in Denmark would manufacture treatments next year.

Lilly had previously said it would make one million doses of its single antibody treatment available by the end of the year, and another 50,000 doses of its dual-antibody therapy by the fourth quarter this year.

Lilly said its partners with which it is developing antibody therapies, including Canadian biotech company AbCellera Biologics Inc, had agreed to waive their royalties on the therapies distributed in low- and middle-income countries.

The drugmaker in September partnered with Amgen Inc to increase supply of its antibody therapies, a day after data showed that Lilly's single antibody therapy, LY-CoV555, helped cut hospitalization and emergency room visits for COVID-19 patients.

Fujifilm said in a statement it expects to begin manufacturing of Lilly's antibody therapy in April 2021. In June, the company said its subsidiary Fujifilm Diosynth Biotechnologies would double capacity at its Danish facility, which it has pledged to use in making COVID-19 treatments.

A dual-antibody combination also showed similar results on Wednesday. Lilly plans to seek U.S. emergency use authorization for that combination next month.

(Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. 2.04% 224.81 Delayed Quote.-8.61%
ELI LILLY AND COMPANY 1.86% 147.44 Delayed Quote.10.13%
FUJIFILM HOLDINGS CORPORATION 0.10% 5756 End-of-day quote.10.06%
All news about FUJIFILM HOLDINGS CORPORATION
11/13FUJIFILM : Cellular Dynamics and Lonza Agree to Expand the Availability and Use ..
AQ
11/05WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remd..
RE
11/05FUJIFILM HOLDINGS CORPORATION : half-yearly earnings release
10/30In Japan's Nagasaki, some glimmers of economic revival
RE
10/22FUJIFILM : Fuji Xerox in court over alleged unfair contract terms
AQ
10/22Dr Reddy's isolates data center services after cyberattack
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/21Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/19Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/16Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
More news
Financials
Sales 2021 2 200 B 21 132 M 21 132 M
Net income 2021 127 B 1 220 M 1 220 M
Net Debt 2021 170 B 1 630 M 1 630 M
P/E ratio 2021 17,9x
Yield 2021 1,68%
Capitalization 2 291 B 22 022 M 22 006 M
EV / Sales 2021 1,12x
EV / Sales 2022 1,05x
Nbr of Employees 73 906
Free-Float 73,8%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 6 164,67 JPY
Last Close Price 5 730,00 JPY
Spread / Highest target 20,4%
Spread / Average Target 7,59%
Spread / Lowest Target -12,4%
EPS Revisions
Managers
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kouichi Tamai Director & Vice President
Takatoshi Ishikawa Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION10.06%22 068
CANON INC.-34.89%19 503
BROTHER INDUSTRIES, LTD.-8.37%5 186
RICOH COMPANY, LTD.-39.60%5 002
TOSHIBA TEC CORPORATION-12.94%2 076
KONICA MINOLTA, INC.-52.31%1 616